NO3175985T3 - - Google Patents

Info

Publication number
NO3175985T3
NO3175985T3 NO16202228A NO16202228A NO3175985T3 NO 3175985 T3 NO3175985 T3 NO 3175985T3 NO 16202228 A NO16202228 A NO 16202228A NO 16202228 A NO16202228 A NO 16202228A NO 3175985 T3 NO3175985 T3 NO 3175985T3
Authority
NO
Norway
Application number
NO16202228A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3175985T3 publication Critical patent/NO3175985T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO16202228A 2011-07-01 2012-05-31 NO3175985T3 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
NO3175985T3 true NO3175985T3 (OSRAM) 2018-04-28

Family

ID=46513864

Family Applications (1)

Application Number Title Priority Date Filing Date
NO16202228A NO3175985T3 (OSRAM) 2011-07-01 2012-05-31

Country Status (20)

Country Link
US (2) US8962610B2 (OSRAM)
EP (2) EP2966067B1 (OSRAM)
JP (3) JP6470969B2 (OSRAM)
KR (1) KR101919634B1 (OSRAM)
CN (2) CN107325111A (OSRAM)
AR (1) AR086829A1 (OSRAM)
AU (1) AU2012279214B2 (OSRAM)
BR (1) BR112013032027A2 (OSRAM)
CA (1) CA2838234A1 (OSRAM)
EA (2) EA031189B1 (OSRAM)
ES (2) ES2657169T3 (OSRAM)
IL (1) IL229714B (OSRAM)
MA (1) MA35808B1 (OSRAM)
MX (1) MX338916B (OSRAM)
NO (1) NO3175985T3 (OSRAM)
PL (2) PL2966067T3 (OSRAM)
PT (2) PT2726469E (OSRAM)
SI (2) SI2966067T1 (OSRAM)
TW (1) TWI466873B (OSRAM)
WO (1) WO2013006463A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
KR101911560B1 (ko) 2010-07-02 2018-10-24 길리애드 사이언시즈, 인코포레이티드 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
EP3404032B1 (en) * 2013-03-13 2025-07-02 F. Hoffmann-La Roche AG Process for making benzoxazepin compounds
SI3317284T1 (sl) 2015-07-02 2020-02-28 F. Hoffmann-La Roche Ag Spojine benzoksazepin oksazolidinona in načini uporabe
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
CN106046021A (zh) * 2016-05-26 2016-10-26 天津药物研究院有限公司 一类含溴的噻吩并吡啶类衍生物及其制备方法和用途
US20180064726A1 (en) 2016-09-08 2018-03-08 Auspex Pharmaceuticals, Inc. Deuterium-Substituted Oxazepin Compounds
CN116763791A (zh) 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
IL309843A (en) 2018-05-30 2024-02-01 Praxis Prec Medicines Inc ion channel modulators
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
KR20230159419A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
EP4495119A4 (en) * 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867616A (en) 1950-05-17 1959-01-06 Syntex Sa 7-dehydro diosgenin compounds and process for making same
US2867618A (en) 1957-02-14 1959-01-06 Dow Chemical Co 3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en) 1957-05-06 1958-03-11 Dow Chemical Co 3, 3'-alkylenebis
NL128591C (OSRAM) 1965-07-02
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
CH482404A (de) 1967-12-14 1969-08-15 Ciba Geigy Verwendung von Arylguanaminen zum antimikrobiellen Ausrüsten bzw. zum Schützen von Textilfasern gegen Mikroorganismen
US3594372A (en) 1968-08-13 1971-07-20 American Home Prod Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
ATE152102T1 (de) 1991-05-10 1997-05-15 Takeda Chemical Industries Ltd Pyridinderivate, deren herstellung und anwendung
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5693636A (en) 1991-06-28 1997-12-02 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5663166A (en) 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH061779A (ja) 1992-02-06 1994-01-11 Wakamoto Pharmaceut Co Ltd ベンズオキサジノン誘導体
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en) 1996-02-19 1998-06-30 Fuji Photo Film Co., Ltd. Heat-sensitive recording material
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
IL128170A0 (en) 1996-07-26 1999-11-30 Nissan Chemical Ind Ltd Chroman derivatives
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
DE19716237A1 (de) 1997-04-18 1998-10-22 Basf Ag Substituierte Benzyloxyimino-Verbindungen
WO1998047885A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
CA2300906A1 (en) 1997-09-08 1999-03-18 Unilever Plc Method for enhancing the activity of an enzyme
YU43800A (sh) 1998-01-21 2002-12-10 Merck Sharp & Dohme Limited Triazolo-piridazin derivati kao ligandi za gaba receptore
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CA2319173A1 (en) 1998-02-11 1999-08-19 Jingwu Duan Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
SK11892000A3 (sk) 1998-02-18 2001-02-12 Neurosearch A/S Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora
CA2334258A1 (en) 1998-06-05 1999-12-09 Icagen, Inc. Potassium channel inhibitors
US6479506B1 (en) 1998-06-16 2002-11-12 Merck Sharp & Dohme Ltd. Triazolo-pyridine derivatives as ligands for GABA receptors
WO2000012492A1 (en) 1998-09-01 2000-03-09 Nissan Chemical Industries, Ltd. Benzoxazine derivatives
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
MXPA01010176A (es) 1999-04-09 2002-03-27 Meiji Seika Kaisha Compuestos heterociclicos que contienen nitrogeno y compuestos de benzamida y farmacos que los contienen.
EP1182195A4 (en) 1999-05-07 2003-03-26 Takeda Chemical Industries Ltd CYCLIC CONNECTIONS AND APPLICATIONS THEREOF
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6121916A (en) 1999-07-16 2000-09-19 Eaton-Vorad Technologies, L.L.C. Method and apparatus for recognizing stationary objects with a moving side-looking radar
JP2003508586A (ja) 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 迅速に作用する処方成分、それらの成分を使用する組成物および洗濯方法
DE60024463T2 (de) 1999-08-27 2006-08-17 The Procter & Gamble Company, Cincinnati Stabile substanzen, zusammensetzungen und waschverfahren zu deren verwendung
CZ2002687A3 (cs) 1999-08-27 2002-09-11 The Procter & Gamble Company Barvu zachovávající prací způsoby používající formulační složky s obojetnými ionty
AU6935800A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Controlled availability of formulation components, compositions and laundry methods employing same
JP2003508587A (ja) 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 安定性増強配合成分、これを用いた組成物および洗濯方法
BR0013647A (pt) 1999-08-27 2002-05-07 Procter & Gamble Métodos de lavagem com proteção á cor empregando componentes de formulação catiÈnicas
JP2003510251A (ja) 1999-08-27 2003-03-18 ザ、プロクター、エンド、ギャンブル、カンパニー ブリーチ増強成分、組成物および洗濯方法
HK1047106B (en) 1999-09-17 2006-04-28 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6555574B1 (en) 1999-09-24 2003-04-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2001046155A1 (en) 1999-12-21 2001-06-28 Icagen, Inc. Potassium channel inhibitors
AU5652001A (en) 2000-05-15 2001-11-26 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2002010135A1 (en) 2000-08-01 2002-02-07 Ono Pharmaceutical Co., Ltd. 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
EP1320530A1 (en) 2000-08-29 2003-06-25 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
WO2002024655A1 (en) 2000-09-20 2002-03-28 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE60123665T2 (de) 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
WO2002072579A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE60206505T2 (de) 2001-06-25 2006-07-06 Nissan Chemical Industries, Ltd. Substituierte benzopyranderivate gegen arrhytmie
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ES2291538T3 (es) 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
BR0313384A (pt) 2002-08-13 2005-07-12 Warner Lambert Co Derivados de cromona como inibidores de metaloproteinases de matriz
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
AU2003262073A1 (en) 2002-09-20 2004-04-08 Tsumura And Co. Antitussives
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
WO2004037192A2 (en) 2002-10-22 2004-05-06 The Trustees Of The University Of Pennsylvania Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
CA2504735C (en) 2002-11-07 2009-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN100430386C (zh) 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
NZ540468A (en) 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
EP1622916A4 (en) 2003-04-17 2008-11-05 Merck & Co Inc Heterocyclic CYCLOPENTYLTETRAHYDROISOCHINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
AU2004233941A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004101509A2 (en) 2003-05-06 2004-11-25 Case Western Reserve University Functionalized benzoxazines, polymers and copolymers thereof
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
AU2004253543B2 (en) 2003-07-01 2009-02-19 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
MXPA06000796A (es) 2003-07-21 2006-04-07 Solvay Pharm Gmbh Uso de los compuestos 3,7-diazabiciclo [3,3,1]nonano para el tratamiento y/o profilaxis de eventos antiarritmicos en pacientes humanos varones.
JP4808156B2 (ja) 2003-08-05 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
DE10348298A1 (de) 2003-10-17 2005-05-19 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte 2-(4-Sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
TW200514582A (en) 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
EP1708709A1 (en) 2003-12-18 2006-10-11 Pfizer Products Incorporated METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS
WO2005085216A1 (ja) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2005121149A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
WO2006020959A2 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
JP2008510810A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合トリアゾール誘導体
CA2579850A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirohydantoin cgrp receptor antagonists
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US20060094003A1 (en) 2004-11-01 2006-05-04 Stanley Nattel Acetylcholine-dependent current as a novel ionic target for atrial fibrillation
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja) 2004-12-24 2006-08-03 Matsushita Electric Ind Co Ltd 受信装置
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
KR100609101B1 (ko) 2005-03-11 2006-08-08 주식회사 신화성물산 물수건 공급장치의 물 분사노즐 및 그 제조방법
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US7714150B2 (en) 2005-04-12 2010-05-11 Solvay Pharmaceuticals Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives
ZA200707473B (en) 2005-04-12 2008-12-31 Solvay Pharm Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3 , 4-dihydro-2H-cromen-6-yl derivatives and their use as potassium channel blockers
US20080176830A1 (en) 2005-04-14 2008-07-24 Adams Nicholas D Compounds, Compositions, and Methods
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
BRPI0611948A2 (pt) 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
CN101258136A (zh) * 2005-07-05 2008-09-03 阿斯利康(瑞典)有限公司 新化合物、其制备方法、中间体、药物组合物和其在治疗5－ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途
GB0516963D0 (en) 2005-08-18 2005-09-28 Carbonite Corp Liquid dispensers
EP1932549B1 (en) 2005-08-26 2016-12-28 AMNOS Co., Ltd. Dried amnion and method for drying treatment of amnion
CA2621255A1 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007038209A2 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
WO2007061677A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
AU2006316646A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam bicyclic CGRP receptor antagonists
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
US20070142376A1 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
RU2008143179A (ru) 2006-03-31 2010-05-10 Новартис АГ (CH) Органические соединения
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
KR20090021218A (ko) 2006-06-12 2009-02-27 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서 유용한 티에노피리미딘
JP2009542673A (ja) 2006-06-29 2009-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
WO2008007661A1 (en) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Tricyclic heterocyclic compound and use thereof
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
GEP20125458B (en) 2006-08-22 2012-03-26 Ranbaxsy Lab Ltd Matrix metalloproteinase inhibitors
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
CA2822776A1 (en) 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
WO2008053913A1 (en) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
US20080153840A1 (en) 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
AU2008219723A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers
EP2123644B1 (en) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
EP2139480A1 (en) 2007-04-12 2010-01-06 CV Therapeutics Inc. Ranolazine for enhancing insulin secretion
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
AU2008298926A1 (en) 2007-09-12 2009-03-19 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2234615A1 (en) 2007-12-19 2010-10-06 Wyeth LLC 4-imidazolidinones as kv1.5 potassium channel inhibitors
CN101903387B (zh) 2007-12-19 2014-05-21 健泰科生物技术公司 8-苯氨基咪唑并吡啶和它们在制备抗癌剂和/或抗炎剂中的用途
CA2709187A1 (en) 2007-12-19 2009-06-25 Wyeth Llc 4-imidazolidinones as kv1.5 potassium channel inhibitors
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009089027A1 (en) 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
WO2009100380A1 (en) 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
CN101910169A (zh) 2008-02-13 2010-12-08 卫材R&D管理有限公司 双环胺衍生物
JP2009286773A (ja) 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
CA2725573A1 (en) 2008-06-06 2009-12-10 Abbott Laboratories Novel 1,2,4 oxadiazole compounds and methods of use thereof
JP5551689B2 (ja) 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
JP2011527708A (ja) 2008-07-11 2011-11-04 ニュメディックス 減少した抗菌活性および神経保護作用の利点を有するテトラサイクリン誘導体
MY147281A (en) 2008-07-31 2012-11-30 Invenpro M Sdn Bhd An apparatus for washing a workpiece
AU2009277232B2 (en) 2008-07-31 2012-03-29 Poh Huay Chua Pet carrier
EP2314583B1 (en) 2008-08-12 2015-02-25 Nippon Soda Co., Ltd. Nitrogenated heterocyclic derivative, and agricultural or horticultural bactericidal agent
CA2734449A1 (en) 2008-08-18 2010-02-25 Ube Industries, Ltd. Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2735653A1 (en) 2008-09-04 2010-03-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010056527A2 (en) 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
WO2010068461A1 (en) 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
CN102232076B (zh) 2008-12-05 2014-12-31 霍夫曼-拉罗奇有限公司 吡咯并吡嗪基脲激酶抑制剂
AU2009333543A1 (en) 2008-12-08 2011-07-07 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
JP5271069B2 (ja) 2008-12-24 2013-08-21 三和シヤッター工業株式会社 開閉装置
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
EP2845592A1 (en) * 2009-09-28 2015-03-11 F. Hoffmann-La Roche AG Benzoxazepin PI3K inhibitor compounds and methods of use
WO2011042920A1 (en) 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US8323911B2 (en) 2010-05-13 2012-12-04 University Of South Carolina High throughput assay for discovering new inhibitors of the GIRK1/4 channel
KR101911560B1 (ko) 2010-07-02 2018-10-24 길리애드 사이언시즈, 인코포레이티드 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
NZ609200A (en) 2010-09-21 2015-01-30 Purdue Pharma Lp Buprenorphine analogs
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
EP2643316A2 (en) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012074469A1 (en) 2010-11-30 2012-06-07 Astrazeneca Ab New ikach blockers
JP5675428B2 (ja) 2011-02-25 2015-02-25 サンドビック株式会社 ベルトプレス装置
US9090628B2 (en) * 2011-03-21 2015-07-28 Genentech, Inc. Benzoxazepin compounds selective for PI3K P110 delta and methods of use
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
EP2714011B1 (en) 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
CA2840518A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
HK1200114A1 (en) 2011-09-21 2015-07-31 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
ES2805341T3 (es) 2012-06-13 2021-02-11 Acesion Pharma Aps Composiciones farmacéuticas para terapia de combinación
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
TW201613908A (en) 2014-02-13 2016-04-16 Gilead Sciences Inc Solid forms of an ion channel modulator
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法

Also Published As

Publication number Publication date
EA031189B1 (ru) 2018-11-30
MX2013014843A (es) 2014-03-31
JP2018203771A (ja) 2018-12-27
US20150239904A1 (en) 2015-08-27
KR101919634B1 (ko) 2018-11-16
AU2012279214B2 (en) 2015-07-30
SI2726469T1 (sl) 2015-10-30
TWI466873B (zh) 2015-01-01
MX338916B (es) 2016-05-03
PT2966067T (pt) 2018-01-30
PL2726469T3 (pl) 2016-01-29
EA201391628A1 (ru) 2014-06-30
EA025095B1 (ru) 2016-11-30
IL229714B (en) 2018-04-30
CN103635467B (zh) 2017-08-04
JP6470969B2 (ja) 2019-02-13
JP2017088630A (ja) 2017-05-25
JP2014518277A (ja) 2014-07-28
CN103635467A (zh) 2014-03-12
US20130005706A1 (en) 2013-01-03
ES2657169T3 (es) 2018-03-01
MA35808B1 (fr) 2014-12-01
BR112013032027A2 (pt) 2016-09-06
EP2966067A1 (en) 2016-01-13
PL2966067T3 (pl) 2018-04-30
HK1197061A1 (en) 2015-01-02
EP2726469B1 (en) 2015-08-12
SI2966067T1 (en) 2018-02-28
IL229714A0 (en) 2014-01-30
CN107325111A (zh) 2017-11-07
HK1219098A1 (en) 2017-03-24
KR20140045394A (ko) 2014-04-16
NZ618684A (en) 2016-02-26
AR086829A1 (es) 2014-01-22
PT2726469E (pt) 2015-10-27
CA2838234A1 (en) 2013-01-10
US8962610B2 (en) 2015-02-24
TW201313692A (zh) 2013-04-01
AU2012279214A1 (en) 2013-05-02
EA201690899A1 (ru) 2016-12-30
EP2966067B1 (en) 2017-10-25
ES2549654T3 (es) 2015-10-30
US9695192B2 (en) 2017-07-04
WO2013006463A1 (en) 2013-01-10
EP2726469A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
BR112013031251A2 (OSRAM)
BR112013027245A2 (OSRAM)
BR112013026905A2 (OSRAM)
BR112013027830A2 (OSRAM)
BR112013027452A2 (OSRAM)
BR112013028733A2 (OSRAM)
BR112013027121A2 (OSRAM)
BR112013031556A2 (OSRAM)
NO3175985T3 (OSRAM)
BR112013032366A2 (OSRAM)
BR112013032377A2 (OSRAM)
BR112013032380A2 (OSRAM)
BR112013027836A2 (OSRAM)
BR112013026895A2 (OSRAM)
BR112013027761A2 (OSRAM)
BR112013032392A2 (OSRAM)
BR112013027871A2 (OSRAM)
BR112013032394A2 (OSRAM)
BR112013030734A2 (OSRAM)
BR112013026861A2 (OSRAM)
BR112013027112A2 (OSRAM)
BR112013027657A2 (OSRAM)
CN301578868S (zh) 盖碗
CN301581816S (zh) 贴花纸(e37043)
CN301542468S (zh) 床上用品面料(11-116)